CTOs on the Move

Happier Living

www.happierliving.com

 
Happier Living is the premier national outpatient private practice that is expanding access to mental health as an in-network organization. We`re a strong community of highly qualified and passionate clinicians focused on long-standing therapeutic relationships with our clients.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.happierliving.com
  • 8235 Santa Monica Blvd Suite 302
    West Hollywood, CA USA 90046
  • Phone: 888.684.2779

Executives

Name Title Contact Details

Similar Companies

Bartels

Bartels is a Issaquah, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EarlySense

EarlySense is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. EarlySense is based in Waltham, MA. You can find more information on EarlySense at www.earlysense.com

Tokai Pharmaceuticals

Tokai Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ride Away Equipment Corp

Here at Ride Away, we offer a competitive benefits package for you and your loved ones. Here is a list of the benefits that Ride Away currently offers: Medical/Dental Insurance Vision Insurance Flex Spending Account (both medical and dependent care)

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic